LMAT
LeMaitre Vascular, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$80.67
+0.22%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 262.4M | 249.6M | 219.9M | 193.5M | 161.7M |
| Cost of Revenue | 71.1M | 71.1M | 69.0M | 66.4M | 56.8M |
| Gross Profit | 191.3M | 178.5M | 150.9M | 127.0M | 104.9M |
| Operating Expenses | |||||
| R&D Expense | 15.4M | 14.1M | 15.7M | 17.0M | 13.3M |
| SG&A Expense | 98.6M | 96.5M | 83.0M | 72.9M | 61.7M |
| General & Admin Expense | 44.3M | 42.0M | 36.3M | 31.8M | 28.7M |
| Selling & Marketing Expense | 54.3M | 54.5M | 46.7M | 41.1M | 32.9M |
| Other Expenses | — | — | — | 485.0K | 3.1M |
| Total Operating Expenses | 114.0M | 110.6M | 98.6M | 90.3M | 78.1M |
| Cost and Expenses | 185.1M | 181.7M | 167.6M | 156.8M | 134.8M |
| Operating Income (EBIT) | 77.3M | 67.9M | 52.3M | 36.7M | 26.8M |
| Non-Operating | |||||
| Interest Income | 10.5M | 13.1M | 4.9M | 3.1M | 986.0K |
| Interest Expense | 5.2M | 5.2M | 205.0K | — | — |
| Net Interest Income | 5.3M | 7.9M | 4.7M | 3.1M | 986.0K |
| Other Non-Op Income/Expense | 7.4M | 7.3M | 4.6M | 2.8M | 661.0K |
| Non-Operating Income (excl Interest) | (6.4M) | (12.5M) | (4.8M) | (2.8M) | (661.0K) |
| EBT (Pre-Tax Income) | 84.7M | 75.2M | 56.9M | 39.5M | 27.5M |
| Income Tax Expense | 19.1M | 17.4M | 12.8M | 9.4M | 6.9M |
| Bottom Line | |||||
| Net Income | 65.7M | 57.7M | 44.0M | 30.1M | 20.6M |
| Earnings from Cont. Ops | 65.7M | 57.7M | 44.0M | 30.1M | 20.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 65.7M | 57.7M | 44.0M | 30.1M | 20.6M |
| Per Share | |||||
| Basic EPS | $2.90 | $2.55 | $1.96 | $1.36 | $0.94 |
| Diluted EPS | $2.85 | $2.52 | $1.93 | $1.34 | $0.93 |
| Revenue Per Share | $11.48 | $11.03 | $9.79 | $8.71 | $7.36 |
| Shares | |||||
| Basic Shares Outstanding | 22.9M | 22.6M | 22.5M | 22.2M | 22.0M |
| Diluted Shares Outstanding | 24.5M | 22.9M | 22.8M | 22.4M | 22.2M |
| Profitability Metrics | |||||
| EBITDA | 97.3M | 90.8M | 66.8M | 49.0M | 36.9M |
| D&A | 13.6M | 10.4M | 9.7M | 9.5M | 9.4M |
| EBIT | 83.7M | 80.4M | 57.1M | 39.5M | 27.5M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026